Table 3.
Comparison of the antitumor efficacy of the induction chemotherapy regimens
| Variable | TPF + CCRT (n = 138) |
PF + CCRT (n = 138) |
Hazard Ratio (95% CI) | P-Value* |
|---|---|---|---|---|
| Progression-free survival | 0.455–1.350 | .380 | ||
| Median duration, months | 34.5 | 34.5 | ||
| Rate, % | ||||
| Two-year | 86.2 | 86.9 | ||
| Three-year (estimated) | 84.5 | 77.9 | ||
| Median duration according to disease stage, months | ||||
| Stage III | 34.5 | 34 | 0.469–2.098 | .984 |
| Stage IV | 34.5 | 35 | 0.294–1.429 | .282 |
| Median duration according to primary tumor category, months | ||||
| T1–2 | 32 | 36 | 0.642–8.084 | .203 |
| T3–4 | 35 | 34 | 0.347–1.168 | .145 |
| Median duration according to nodal category, months | ||||
| N0–1 | 34.5 | 34.5 | 0.358–2.948 | .960 |
| N2–3 | 34.5 | 34.5 | 0.379–1.351 | .302 |
| Overall survival | ||||
| Median duration, months | 36 | 35 | 0.455–1.866 | .821 |
| Rate, % | ||||
| At 2 years | 95.7 | 93.9 | ||
| At 3 years | 91.1 | 91.1 | ||
| Median duration according to disease stage, months | ||||
| III | 36 | 37 | 0.407–3.634 | .726 |
| IV | 35.5 | 35.5 | 0.303–1.960 | .584 |
| Median duration according to primary tumor category, months | ||||
| T1–2 | 37 | 38 | 0–3.951E+228 | .962 |
| T3–4 | 35 | 34 | 0.342–1.527 | .394 |
| Median duration according to nodal category, months | ||||
| N0–1 | 36 | 35 | 0.247–2.662 | .730 |
| N2–3 | 36 | 35 | 0.411–2.383 | .981 |
| Sites of treatment failure | ||||
| Locoregional failure, n (%) | ||||
| Primary | 10 (7.2) | 16 (11.6) | ||
| Neck | 4 (2.9) | 4 (2.9) | ||
| Distant metastases, n (%) | ||||
| Distant only | 10 (7.2) | 9 (6.5) | ||
| Distant and locoregional | 2 (1.4) | 3 (2.2) |
*
Calculated using the Kaplan–Meier method.